Drug intelligence / Profile preview

SLC-021

Development stage: Preclinical
Lead developer: Savior Lifetec
Modality: Peptides
Administration: Parenteral

Overview

SLC-021 is a peptide-based therapeutic candidate currently in preclinical development by Savior Lifetec. The drug is designed as a sterile injection, leveraging the company's specialized technology platform for high-technology, high-unit-cost niche products. While specific indications and biological targets have not been publicly disclosed, the program is part of Savior Lifetec's strategic expansion into the peptide market, focusing on complex injectable formulations and niche generics.

Beyond the preview

Go deeper on SLC-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLC-021.

Explore the full profile